BTIG cuts Tempus AI stock price target to $70 on model update
BTIG cut its Tempus AI (NASDAQ:TEM) price target to $70 from $80 while keeping a Buy rating after the company’s Q2 2026 earnings call. Tempus AI reported 22% YoY revenue growth, raised 2026 revenue guidance to 25% to 26%, and posted $382.5M revenue with an adjusted EPS loss of $0.04. BTIG cited Tempus’s $1.5B Personalis deal with a $46 stock-price termination trigger.
How this was made
The 30-second read
Why it matters
For traders, the key new angle is the combination of a lower analyst price target and a deal-termination provision tied to TEM trading below $46, which can create a self-reinforcing risk premium near the trigger level.
Market read
Analyst target reduction plus a hard stock-price trigger in the Personalis deal raises near-term trading sensitivity for TEM around the $46 level.
What to watch
The article notes only that TEM was near the $46 threshold at report time; actual probability of termination depends on subsequent trading path and any renegotiation or interpretation of the clause.
Background
BTIG updated its Tempus AI model after the company’s Q2 2026 earnings call, the first full quarter post Ambry Genetics acquisition.
Ticker impact
BTIG cut Tempus AI’s price target to $70 from $80 after updating its model post Q2 earnings call, keeping a Buy rating.
Choppy-to-soft bias if TEM remains near $46, with heightened sensitivity to any further guidance or deal-related updates.
The article combines a fresh analyst model update (PT cut) with a concrete deal risk trigger tied to TEM’s share price, while also noting raised 2026 revenue guidance and a narrower-than-expected loss.
Market effects
Highlights how oncology diagnostics and data companies’ deal structures can embed stock-price triggers that amplify volatility.
Limited, primarily affects US small/mid-cap healthcare diagnostics sentiment.
Low, deal and analyst update are company-specific.
Counterpoint
The PT cut may be more about valuation than fundamentals, and raised 2026 revenue guidance plus improved adjusted loss could offset deal-trigger fears.
Key entities
- companyTempus AI Inc
NASDAQ-listed oncology data and diagnostics company; BTIG lowered its price target to $70 and discussed deal risk tied to the Personalis acquisition.
- companyPersonalis
Target in Tempus AI’s announced acquisition, with a termination provision tied to Tempus AI’s stock price below $46.
- analyst_firmBTIG
Issued the price target cut to $70 from $80 while maintaining a Buy rating after updating its model post Q2 call.
